Gynecologic Cancer

Adavosertib alone and in combination with olaparib demonstrated efficacy among women with poly(ADP-ribose) polymerase (PARP) inhibitor-resistant ovarian cancer, according to study results presented during the virtual ASCO Annual Meeting.

Adjuvant chemotherapy following chemoradiation did not prolong OS or PFS compared with chemoradiation alone among women with locally advanced cervical cancer, according to results of the randomized phase 3 OUTBACK study.

The FDA granted breakthrough therapy designation to VS-6766 with defactinib for treatment of recurrent low-grade serous ovarian cancer, according to the agents’ manufacturer.

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology.

Incidence of cervical cancer declined as rates of other HPV-associated cancers increased significantly in the U.S. from 2001 to 2017, according to a population-based study of trends presented during the virtual ASCO Annual Meeting.

The FDA granted priority review to pembrolizumab plus lenvatinib for treatment of advanced renal cell carcinoma and advanced endometrial carcinoma, according to the agents’ manufacturers.

Adavosertib demonstrated clinical activity among women with recurrent uterine serous carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.

Chemotherapy-induced nausea remains a significant clinical problem, but severity varies based on multiple factors, according to results presented during the virtual Oncology Nursing Society Congress.

Mijin Kim, PhD, has been selected to receive a 2021 Marie-Josée Kravis Women in Science Endeavor fellowship grant for her work on a novel sensor technology designed for early detection of ovarian cancer.

The FDA granted accelerated approval to dostarlimab-gxly for treatment of certain women with endometrial cancer.